51
|
Pauly V, Frauger E, Rouby F, Sirere S, Monier S, Paulet C, Gibaga V, Micallef J, Thirion X. Évaluation des conduites addictives chez les personnes entrant en milieu pénitentiaire à partir du programme OPPIDUM du réseau des centres d’évaluation et d’information sur la pharmacodépendance (CEIP). Encephale 2010; 36:122-31. [DOI: 10.1016/j.encep.2009.03.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2008] [Accepted: 03/16/2009] [Indexed: 11/15/2022]
|
52
|
Lièvre M, Costagliola D, Evans S, Fourrier A, Imbs JL, Levy-Bruhl D, Merle L, Micallef J, Oger E. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009; 73:1426-7. [PMID: 19858469 DOI: 10.1212/wnl.0b013e3181bd1f7e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
53
|
Thirion X, Miloudi S, Orléans V, Pauly V, Frauger-Ousset E, Pradel V, Micallef J. Le Programme d’observation des pharmacodépendances en médecine ambulatoire (Opema) : résultats de la première enquête. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
54
|
Pauly V, Frauger-Ousset E, Pradel V, Micallef J, Thirion X. Comparaison de deux méthodes d’évaluation du potentiel d’abus de médicaments à partir des données de l’assurance-maladie : à propos de la buprénorphine haut dosage. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
55
|
Frauger-Ousset E, Pauly V, Thirion X, Natali F, Pradel V, Rouby F, Reggio P, Coudert H, Micallef J. Quelles sont les caractéristiques des sujets qui ont une délivrance de méthylphénidate ? Apport d’une méthode développée à partir des données de l’assurance-maladie. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
56
|
Frauger-Ousset E, Pauly V, Thirion X, Natali F, Pradel V, Reggio P, Coudert H, Micallef J. Évaluation du détournement d’usage du clonazépam à partir de la base de données de l’assurance-maladie. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
57
|
Kilani M, Micallef J, Soubrouillard C, Rey-Lardiller D, Dematteï C, Dib M, Philippot P, Ceccaldi M, Pouget J, Blin O. A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. ACTA ACUST UNITED AC 2009; 5:46-54. [PMID: 15204024 DOI: 10.1080/14660820310017560] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVES The study aimed to evaluate cognitive function and emotional reactivity in 18 patients with ALS, compared to 19 matched controls, and assess their evolution over a 12-month period. METHODS 18 ALS patients and 19 matched controls were included, and assessed at inclusion, six months and twelve months later. Depression was evaluated with the Geriatric Depression Scale, and cognitive function with the Folstein Mini Mental State. A battery of psychometric tests (Wisconsin Card Sorting Test (WCST), the numerical Empan test, the Trail-making test, the Boston Naming Test, the 15-word Rey memory test, the Benton visual retention test and the Raven Progressive Matrix) was used to measure frontal processing and non-frontal function. Emotional reactivity was measured with the film-evoked emotions test. RESULTS ALS patients were significantly more depressed than controls, as measured on the Geriatric Depression Scale, and depression increased over the study period. There was a very mild defect in cognitive function, and a performance deficit in the Trail-making test, a measure of frontal processing. These deficits, unlike neuromuscular function and depression, did not aggravate over the 12 months of the study. There was no observable change in non-frontal function. Emotional reactivity did not differ significantly between ALS patients and controls. CONCLUSIONS This study provides further evidence for a mild defect in frontal cognitive processing in ALS patients that evolves only slowly, if at all, with time.
Collapse
|
58
|
Massol J, Puech A, Boissel JP, Alperovitch A, Bamberger M, Begaud B, Blin O, Blin P, Breart G, Brun Strang C, Buyse M, Castot A, Chauvenet M, Chicoye A, David N, De Bels F, De Sahb Berkovitch R, Dohin E, Fagnani F, Falissard B, Gastaldi-Menager C, Giri I, Haim M, Joubert J, Lapeyre-Mestre M, Lassale C, Marchant Ramirez I, Meyer F, Micallef J, Mollimard M, Moreau-Defarges T, Pazart L, Perret L, Pigeon M, Rumeau Pichon C, Tcheng P, Woler M, Zanetti L, Zylberman M. How to Anticipate the Assessment of the Public Health Benefit of New Medicines? Therapie 2007; 62:427-35. [DOI: 10.2515/therapie:2007071] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2007] [Indexed: 11/20/2022]
|
59
|
Massol J, Puech A, Boissel JP, Alperovitch A, Bamberger M, Bégaud B, Blin O, Blin P, Bréart G, Brun Strang C, Buyse M, Castot A, Chauvenet M, Chicoye A, David N, De Bels F, De Sahb Berkovitch R, Dohin E, Fagnani F, Falissard B, Gastaldi-Menager C, Giri I, Haim M, Joubert J, Lapeyre-Mestre M, Lassale C, Marchant Ramirez I, Meyer F, Micallef J, Mollimard M, Moreau-Defarges T, Pazart L, Perret L, Pigeon M, Rumeau Pichon C, Tcheng P, Woler M, Zanetti L, Zylberman M. Comment anticiper l’évaluation de l’intérêt de santé publique des médicaments ? Therapie 2007; 62:417-25. [DOI: 10.2515/therapie:2007072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2007] [Accepted: 10/05/2007] [Indexed: 11/20/2022]
|
60
|
Massol J, Zylberman M, Goehrs JM, Abenhaïm L, Ambrosi P, Bardou M, Boissel JP, Brun C, Castaigne A, Chassany O, de Bels F, de Sahb-Berkovitch R, El-Hasnaoui A, Fagagni F, Fourrier-Reglat A, Gastaldi-Meninger C, Goehrs JM, Gueffier F, Hotton JM, Ichou F, Lechat P, Maillère P, Meyer F, Micallef J, Molimard M, Moreau-Defarges T, Perillat A, Pigeon M, Poitrinal P, Rey-Quino C, Ricordeau P, Ropers J. Utilisation des études étrangères : transposition des résultats, prédiction des effets thérapeutiques en population française, modélisation de l’Intérêt de Santé Publique. Therapie 2006; 61:481-9. [DOI: 10.2515/therapie:2007002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
61
|
Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore GJ. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect 2006; 135:144-50. [PMID: 16707030 PMCID: PMC2870537 DOI: 10.1017/s0950268806006388] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2006] [Indexed: 01/09/2023] Open
Abstract
Estimates of hepatitis C virus (HCV) clearance following acute infection range from 14 to 46%. This wide range is likely to be due to the characteristics of the populations studied and analysis methods. This paper examines how differing definitions of clearance parameters affect estimates of viral clearance in a cohort of 85 injecting drug users with newly acquired HCV infection. Kaplan-Meier estimates of time to HCV clearance were determined using varying definitions of eligible cohort, viral clearance, date of infection and date of clearance. Based on which combinations of definitions were used, the number of subjects eligible for analysis ranged from 27 to 75, clearance rate ranged from 14 to 68% and time to achieving 25% clearance ranged from approximately 5 months to 14 months. Standardized definitions and methodologies are required to enable valid comparisons of rates of clearance across newly acquired HCV infection natural history studies.
Collapse
|
62
|
Micallef J, Fakra E, Blin O. Intérêt des antidépresseurs chez le patient schizophrène présentant un syndrome dépressif. Encephale 2006; 32:263-9. [PMID: 16910628 DOI: 10.1016/s0013-7006(06)76153-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Depression is common in people with schizophrenia and is associated with substantial morbidity explaining also the considerable attention and recognition of this entity as suggested by the inclusion of the post-psychotic depression in DSM IV and ICD 10. The prevalence of this disorder varies according to the type of approach used (range between 7% to 75%). Prescription of antidepressants plus antipsychotic treatment is frequent in clinical practice (11 to 43%). BACKGROUND Pharmacokinetic and metabolic interactions have been identified. The cytochrome P450 has been identified as being implicated in the metabolism of most psychotropics, mainly through the CYP1A2, CYP2C19, CYP2D6, CYP3A4 isoenzymes. Tricyclic antidepressants are likely to increase chlorpromazine plasma levels. Similarly, antipsychotics such as perphenazine, chlorpromazine or haloperidol can increase antidepressant plasma levels, through the inhibition of CYP 450 isoenzymes (CYP2D6). Most of the Specific Serotonin Recapture Inhibitors (SSRIs) are likely to inhibit one or several CYP450 isoenzymes. The inhibition is moderate to marked for CYP1A2 (fluvoxamine and fluoxetine), CYP2C19 (fluoxetine, fluvoxamine and sertraline), CYP2D6 (paroxetine, fluoxetine and sertraline), and CYP3A4 (fluvoxamine, fluoxetine and sertraline). In the US, one-fourth of psychiatrists report the use of depression-rating scales in schizophrenic patients. Non specific scales (Hamilton Depression Rating Scale or Beck Depression Inventory) are the most commonly used in spite of the fact that these scales do not allow the distinction of depressive from negative symptoms in schizophrenic patients. LITERATURE FINDINGS Due to these limitations, more specific assessment tools for depressive symptoms in schizophrenia are required. Two specific scales for assessing depressive symptoms in schizophrenic patients have been constructed and validated. The Calgary Depression Scale (CDS) is a nine item scale, each item scored from 0 to 3. This scale was derived from the HDRS and the Present State Examination. Factor analysis showed that the CDS is unidimensional, has high internal consistency, and significant strong correlation with scores on the HDRS, Beck and BPRS depression scales. The CDS has been validated in different languages (Brazilian, Danish, French...). It has been shown that there is no overlap between negative or extrapyramidal and depressive symptoms assessed by the PDS in schizophrenic patients. The Psychotic Depression Scale (PDS) is a 32 item scale derived from the HDRS, PANSS, CPRS and AMDP, each item being rated from 0 to 7. A principal component analysis of the PDS items using a Varimax rotation disclosed 8 orthogonal components that account for 71% of the variance. These components involved the following dimensions : depressive mood, inhibition, vegetative signs, paranoid signs, strangeness of thought, inverse vegetative signs, guilt feelings and cognitive signs. The analysis revealed that the 'depressive mood' factor of the PDS was correlated with the 'depressive' factor and was slightly correlated with the cognitive factor of the PANSS. This first factor was not correlated with either the "negative" factor of the PANSS, or the Positive or Excitement factor of the PANSS. Hence, this PDS, factor distinguished depressive signs from negative symptoms. Due to their metrologic properties, specific scales should be preferred. However, only one open trial (of an antipsychotic) and two double blind controlled trials (one comparison of 2 antipsychotics and one comparison of an cholinesterase inhibitor versus placebo) have been published using the CDS. Likewise, only one double blind controlled trial using the PDS (comparison of 2 antipsychotics) has been published. No study of the effect of antidepressants in depressed schizophrenic patients has been published, using either the CDS or the PDS assessment criteria. DISCUSSION These specific scales are rarely used in clinical practice. Only about 1% of the US psychiatrists reported the use of the Calgary Depression Scale. Several open clinical trials have assessed the efficacy of antidepressant agents added to antipsychotic in patients with schizophrenia. They have produced inconsistent results but have suffered from methodological limits (short duration of the studies, non homogeneous inclusion criteria, heterogeneous assessment methods...). Due to the lack of a reference drug, double blind placebo-controlled trial are necessary. A recent meta-analysis has been performed on results of trials that have investigated the clinical efficacy of antidepressant medication (either tricyclics, SSRIs or others) in the treatment of depression in schizophrenic patients. In a subset of 5 trials (209 patients), the proportion improved in the antidepressant group was 26% (95% CI 10 to 42) higher than in the placebo group. The estimated number needed to treat was 4. In a subgroup of 6 studies (267 patients), the standardized mean difference on the HDRS score was -0.27 (95% CI - 0.7 to -0.2). There was no evidence that antidepressant treatment induced a deterioration of psychotic symptoms in these trials. CONCLUSION The results provide weak evidence for the efficacy of antidepressants in patients with schizophrenia and depression. Today, the only SSRI tested in the treatment of depression in schizophrenic patients is sertraline. One study led to positive results. Since the meta-analysis, one additional study has been performed comparing sertraline to placebo. No difference between the 2 treatment groups was demonstrated but the power of the trial was rather low. Further research is required to determine the best approach towards treating depression in patients with schizophrenia, with clinical trials performed for longer periods, using appropriate assessment criteria such as depressive symptoms and quality of life.
Collapse
|
63
|
Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21:139-49. [PMID: 16625522 DOI: 10.1002/hup.757] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Adjustment Disorders With Anxiety (ADWA) account for almost 10% of psychologically motivated consultations in primary care. The aim of this double-blind randomised parallel group study was to compare (non-inferiority test) the efficacies of etifoxine, a non-benzodiazepine anxiolytic drug, and lorazepam, a benzodiazepine, for ADWA outpatients followed by general practitioners. 191 outpatients (mean age: 43, female: 66%) were assigned to receive etifoxine (50 mg tid) or lorazepam (0.5-0.5-1 mg /day) for 28 days. Efficacy was evaluated on days 7 and 28 of the treatment. The main efficacy assessment criterion was the Hamilton Rating Scale for Anxiety score (HAM-A) on Day 28 adjusted to Day 0. The anxiolytic effect of etifoxine was found not inferior to that of lorazepam (HAM-A score decrease: 54.6% vs 52.3%, respectively, p=0.0006). The two drugs were equivalent on Day 28. However, more etifoxine recipients responded to the treatment (HAM-A score decreased by >or=50%, p=0.03). Clinical improvement (based on Clinical Global Impression scale CGI, Social Adjustment Scale Self-Report SAS-SR, and Sheehan scores) was observed in both treatment arms, but more etifoxine patients improved markedly (p=0.03) and had a marked therapeutic effect without side effects as assessed by CGI, p=0.04. Moreover, 1 week after stopping treatment, fewer patients taking etifoxine experienced a rebound of anxiety, compared to lorazepam (1 and 8, respectively, p=0.034).
Collapse
|
64
|
Guillemot D, France G, Fender P, Alexandre JM, Amede-Manesme O, Bader JP, Bouhassira M, Calles B, Castaigne A, Chauvenet M, Diquet B, Giri I, Ichou F, Jolliet P, Joubert JM, Lehner JP, Lièvre M, Mathiex-Fortunet H, Marty M, Meyer F, Micallef J, Pigeon M, Rouveix B, Zannad F. Methodology for the Evaluation and Measurement of Therapeutic Progress. Therapie 2005. [DOI: 10.2515/therapie:2005052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
65
|
Blin O, Fakra E, Delaveau P, Micallef J. Pharmacological control of emotional processes. Rev Neurol (Paris) 2004. [DOI: 10.1016/s0035-3787(04)71224-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
66
|
Weisser C, Micallef J, Ghisla R, Waibel P. Cerebrale av-Malformation als Ursache einer neonatalen Herzinsuffizienz. Z Geburtshilfe Neonatol 2004. [DOI: 10.1055/s-2004-829393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
67
|
Weisser C, Micallef J, Hanimann B. Abdominelles Kompartment-Syndrom bei einem Neugeborenen mit Neuroblastom Stadium IV S. Z Geburtshilfe Neonatol 2004. [DOI: 10.1055/s-2004-829233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
68
|
Girard P, Cucherat M, Guez D, Boissel JP, Cucherat M, Durrleman S, Girard P, Guez D, Koen R, Laveille C, Mathiex-Fortunet H, Micallef J, Missoum N, Paintaud G, Perault MC, Tansey M, Thomas JL, Treluyer JM, Variol P, Waegemans T. Clinical Trial Simulation in Drug Development. Therapie 2004. [DOI: 10.2515/therapie:2004057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
69
|
Ancolio C, Tardieu S, Soubrouillard C, Alquier C, Pradel V, Micallef J, Blin O. A randomized clinical trial comparing doses and efficacy of lormetazepam tablets or oral solution for insomnia in a general practice setting. Hum Psychopharmacol 2004; 19:129-34. [PMID: 14994324 DOI: 10.1002/hup.572] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Lormetazepam is a short-acting benzodiazepine hypnotic which is beneficial in shortening the time to onset of sleep. The aim of the study was to assess a new formulation of lormetazepam (oral solution) in comparison with lormetazepam tablets in out-patients with insomnia. This trial was an open randomized parallel group study conducted by 30 general practitioners. One hundred and eight patients took 0.5 mg on the first night and were allowed to increase their dosage by 0.25 mg (for oral solution) and 0.5 mg (for tablets), respectively, each day and every 2 days. The patients assessed the efficacy, acceptability and tolerance of lormetazepam using a diary card and a set of visual analogue scales assessing their sleep. Over 14 days of treatment, the mean daily dose of lormetazepam was lower in the oral solution group than in the tablets group (0.78 mg versus 0.97 mg). The cumulated dose of lormetazepam was lower with the oral solution (18% reduction). No significant difference between the two groups was found in the assessment of sleep characteristics. The occurrence of side effects did not differ between the two groups. These results suggest that a unitary dose as achieved by an oral solution of lormetazepam allows easier determination of the minimal individual effective dose.
Collapse
|
70
|
Tardieu S, Poirier Y, Micallef J, Blin O. Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. Acta Psychiatr Scand 2004; 109:75-7; discussion 77-8. [PMID: 14674962 DOI: 10.1111/j.0001-690x.2004.t01-1-00196.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Bupropion sustained release is considered to be a weak inhibitor of dopamine and serotonin reuptake. METHOD We report the case of an amphetamine-abusing patient who self-administered bupropion. RESULTS Since 30 years, a 52-year-old women used amphetamine derivates. She explained her need for amphetamine use in order to perform daily activities. Recently, she decided to experiment with bupropion. She abruptly stopped taking clobenzorex and simultaneously started taking bupropion (150 mg/day). The seventh day she reported a concomitant intake of clobenzorex; this induced adverse effects. Whilst taking bupropion, she described experiencing an euthymic state without any compulsion to take amphetamine drugs and was able to perform daily activities. After stopping it, no symptoms of withdrawal were reported by the patient. CONCLUSION This observation supports an another report suggesting that bupropion may be of help in weaning from amphetamine users and should be confirmed by clinical trials.
Collapse
|
71
|
Abstract
Anti-psychotic medications are an important therapeutic option for many individuals with schizophrenia. Recently, a growing interest has been observed on weight gain, which is now a well-known adverse effect of many anti-psychotics. As obesity is frequently a comorbid condition with schizophrenia, patients with schizophrenia are inherently at increased risk of developing obesity-related conditions such as cardiovascular disease and type 2 diabetes. The consequences of excessive weight gain (obesity) associated with anti-psychotic drugs are likely to include adverse effects on health, social burden and poor compliance or even discontinuation of therapy by the patients. In this article, we focus on different aspects of weight gain induced by anti-psychotics. This review comprises the following sections: (i) the pharmacological basis of anti-psychotic-induced weight gain and metabolic effects with a review of all anti-psychotics that can be used in patients with schizophrenia; (ii) the clinical impact of the body weight gain (morbidity, psychatric consequences, mortality); (iii) the management of obesity (identification of risk factors including pharmacogenetics, diet, behavioural therapies, pharmacological approach). An understanding of these aspects is important for those who prescribe anti-psychotics in order to provide the patient the best therapeutic management.
Collapse
|
72
|
Micallef J, Tardieu S, Gentile S, Fakra E, Jouve E, Sambuc R, Blin O. [Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects]. Neurophysiol Clin 2003; 33:138-47. [PMID: 12909392 DOI: 10.1016/s0987-7053(03)00028-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Schizophrenic patients suffer from positive (delusions, hallucinations) and negative signs (social withdrawal) as well as emotional disturbance that included quantitative (blunted affect) and qualitative impairments (discordance of emotional level). Ketamine, a phencyclidine derivative, is a non competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist. In healthy subjects its administration induces some positive symptoms (perceptual distortions.), negative symptoms (emotional deficit, apathy, social withdrawal) and cognitive changes (memory impairments and perseverations) that resemble some aspects of the symptoms of schizophrenia. A double blind cross over, placebo controlled was performed in 12 normal subjects with 2 sessions separated by one week of wash-out to determine ketamine-induced effects on behavioral and emotional responses. During each session, subjects received either ketamine or placebo (saline) infusion. A subanesthetic dose of ketamine (0,5 mg/kg) was administered by constant perfusion over 60 min. Behavioral and cognitive responses were assessed using positive and negative symptoms scales (BPRS, items from SAPS and SANS), vigilance and mood visual analog scale, subjective feelings using the Addiction Research Center Inventory (ARCI) and the Profile of Mood States (POMS). Using Philippot's method, emotions were elicited by films segments which induce a diversity of predictable emotions (fear, anger, sadness, joy, disgust and neutral state) and emotional responses were assessed by the Differential Emotions Scale (DES Izard). Low dose of ketamine induced significant effects on 7-items BPRS score (positive and negative items) and significant effects on positive and negative symptoms from SANS and SAPS. This was associated with emotional blunting of visually-induced responses that resemble aspects of schizophrenic emotional impairments. Ketamine impaired ARCI subscales (benzedrine subscale, pentobarbital-chlorpromazine subscale and LSD subscale). The recent findings of ketamine's pharmacology and imaging studies allow to draw several hypothesis related to neurotransmitter systems (glutamate, dopamine, serotonin interactions) and cerebral areas (particularly prefrontal cortex, anterior cingulate cortex, hippocampus) underlying some of these ketamine-induced effects.
Collapse
|
73
|
Tardieu S, Becker H, Micallef J, Blin O. [Treatment of non-dopamine-dependent signs in parkinsonian syndromes: evaluation and results]. Rev Neurol (Paris) 2003; 159:3S87-92. [PMID: 12773893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
With dopaminergic systems, non dopaminergic neurotransmission probably plays a major role in parkinsonian syndromes (Multiple System Atrophy, Progressive Supranuclear Palsy, Pure Autonomic Failure, Cortical basal degeneration, Lewy Body Disease). A better understanding of the pathophysiology of these syndromes led to the development of molecules that interact with non dopaminergic systems. Thus, freezing, gait and balance disorders, dysautonomia and neuropsychiatric disorders are likely to benefit from specific treatments. However, due to methodological difficulties related to the evaluation of such molecules, controlled trials are rather rare and the results are often partial and sometimes unclear.
Collapse
|
74
|
Le Galès C, El Hasnaoui A, Goehrs JM, Banzet M, Blachier C, Blin P, Bouhassira M, Bouvenot G, Bréart G, Daurès J, de Cremiers F, Duguay C, Eschwege E, Fagnani F, Fontbonne-Bayner A, Giri I, Hotton J, Ichou F, Jolliet P, Joubert J, Koen R, Lagarde D, Le Jeunne C, Leutenegger E, Marquet T, Massol J, Meyer F, Micallef J, Paulmier-Bigot S, Ploin P, Ract Y, Rauss A, Ricatte M, Sainte-Marie H, Tardieu S, Vesque D, Vetel J, Vray M, Watteau P. Postmarketing Evaluation of Drugs. Therapie 2003. [DOI: 10.2515/therapie:2003034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
75
|
Blin O, Fakra E, Tardieu S, Micallef J. [From neuroleptics to antipsychotics: the cognitive and emotional impact]. L'ENCEPHALE 2002; 28 Spec No 2 Pt 2:S16-8. [PMID: 12587350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
|